病毒
冠状病毒
适体
病毒学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
血管紧张素转化酶2
化学
2019年冠状病毒病(COVID-19)
分子生物学
生物
医学
传染病(医学专业)
病理
疾病
作者
Sachindra S. T. Gamage,Thilanga N. Pahattuge,Harshani Wijerathne,Katie Childers,Swarnagowri Vaidyanathan,Uditha S. Athapattu,Lulu Zhang,Zheng Zhao,Mateusz L. Hupert,Rolf Muller,Judy Muller‐Cohn,Janet Dickerson,Dylan Dufek,Brian V. Geisbrecht,Harsh B. Pathak,Ziyan Y. Pessetto,Gregory N. Gan,Junseo Choi,Sunggook Park,Andrew K. Godwin
出处
期刊:Science Advances
[American Association for the Advancement of Science]
日期:2022-09-28
卷期号:8 (39)
被引量:22
标识
DOI:10.1126/sciadv.abn9665
摘要
We report a microfluidic assay to select active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral particles (VPs), which were defined as intact particles with an accessible angiotensin-converting enzyme 2 receptor binding domain (RBD) on the spike (S) protein, from clinical samples. Affinity selection of SARS-CoV-2 particles was carried out using injection molded microfluidic chips, which allow for high-scale production to accommodate large-scale screening. The microfluidic contained a surface-bound aptamer directed against the virus's S protein RBD to affinity select SARS-CoV-2 VPs. Following selection (~94% recovery), the VPs were released from the chip's surface using a blue light light-emitting diode (89% efficiency). Selected SARS-CoV-2 VP enumeration was carried out using reverse transcription quantitative polymerase chain reaction. The VP selection assay successfully identified healthy donors (clinical specificity = 100%) and 19 of 20 patients with coronavirus disease 2019 (COVID-19) (95% sensitivity). In 15 patients with COVID-19, the presence of active SARS-CoV-2 VPs was found. The chip can be reprogrammed for any VP or exosomes by simply changing the affinity agent.
科研通智能强力驱动
Strongly Powered by AbleSci AI